Clinical Trial Update: Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating repeated doses of ecallantide (DX-88) for treatment of attacks in hereditary angioedema (HAE).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Ecallantide (ecallantide)

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: COMPLETED | Results posted: 2012-12-28